<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266149</url>
  </required_header>
  <id_info>
    <org_study_id>LMS: j.nr. 2612-2188</org_study_id>
    <secondary_id>EK:j. nr. 20030009</secondary_id>
    <nct_id>NCT00266149</nct_id>
  </id_info>
  <brief_title>Lamotrigine and Oral Contraceptives</brief_title>
  <official_title>Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <brief_summary>
    <textblock>
      The present study evaluates the effect of oral contraceptives on lamotrigine plasma&#xD;
      concentrations in a double blind, placebo controlled, cross-over study in patients with&#xD;
      epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lamotrigine is widely used as an antiepileptic drug in the treatment of newly onset as well&#xD;
      as refractory epilepsy (1;2). Lamotrigine is unique among the antiepileptic drug since the&#xD;
      major route (76%) of elimination is conjugation with glucuronic acid (glucuronidation) (3).&#xD;
      This conjugation reaction is catalyzed by the uridine 5'-diphosphate&#xD;
      (UDP)-glucuronosyltransferases (UGTs); of which the isoform UGT1A4 probably is the major&#xD;
      route of metabolism in humans (3). The pathway is inhibited by valproate and induced by other&#xD;
      anticonvulsants (3), and explains the effect of these drugs on lamotrgine metabolism (4).&#xD;
      Other drugs that are metabolized via direct glucoronidation may interfere with the metabolism&#xD;
      of lamotrigine e.g. acetaminophen (5). Estrogeneous substrates are metabolized via&#xD;
      glucuronidation (6-8) and may potentially interact with the metabolism of lamotrigine. In the&#xD;
      development of lamotrigine for use in epilepsy patients the effect on the oral contraceptive&#xD;
      pill was studied. In contrast to other commonly used antiepileptic drugs e.g. carbamazepine&#xD;
      and phenytoin(9), lamotrigine did not significantly influence the constituents of the oral&#xD;
      contraceptive pill (10-12). In addition, it was initially assumed from population&#xD;
      pharmacokinetic studies, that oral contraceptives did not influence the metabolism of&#xD;
      lamotrigine (13).However, recent retrospective studies indicate that oral contraceptives may&#xD;
      increase the metabolism of lamotrigine resulting in a significant decrease in plasma&#xD;
      concentration of lamotrigine when given with oral contraceptives (14;15). This effect is&#xD;
      probably related to the ethinyl estradiol content of the combined contracetive pill and no&#xD;
      the progesterone content (16).&#xD;
&#xD;
      To confirm and further extend these findings, the present study evaluates the effect of oral&#xD;
      contraceptives on lamotrigine plasma concentrations in a double blind, placebo controlled,&#xD;
      cross-over study in patients with epilepsy.&#xD;
&#xD;
      Reference List&#xD;
&#xD;
        1. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL et al. Efficacy and&#xD;
           Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy:&#xD;
           Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the&#xD;
           American Epilepsy Society. Epilepsia 2004; 45(5):410-423.&#xD;
&#xD;
        2. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL et al. Efficacy and&#xD;
           Tolerability of the New Antiepileptic Drugs, I: Treatment of New-Onset Epilepsy: Report&#xD;
           of the TTA and QSS Subcommittees of the American Academy of Neurology and the American&#xD;
           Epilepsy Society. Epilepsia 2004; 45(5):401-409.&#xD;
&#xD;
        3. Dickins M, Chen C. Lamotrigine. Chemistry, Biotransformation and Pharmacokinetics. In:&#xD;
           Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic Drugs. Philidelphia:&#xD;
           Lippincott, Williams &amp; Wilkins, 2002: 370-379.&#xD;
&#xD;
        4. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general&#xD;
           features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2(6):347-356.&#xD;
&#xD;
        5. Depot M, Powell JR, Messenheimer JAJ, Cloutier G, Dalton MJ. Kinetic effects of multiple&#xD;
           oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther&#xD;
           1990; 48(4):346-355.&#xD;
&#xD;
        6. Tephly TR, Green MD. UDP-Glucuronosyltransferases. In: Levy RH, Thummel KE, Trager W,&#xD;
           Hansten PD, Eichelbaum M, editors. Metabolic Drug Interactions. Philidelphia:&#xD;
           Lippincott, Williams &amp; Wilkins, 2000: 161-174.&#xD;
&#xD;
        7. Shipkova M, Wieland E. Glucuronidation in therapeutic drug monitoring. Clin Chim Acta&#xD;
           2005; 358(1-2):2-23.&#xD;
&#xD;
        8. Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyzes&#xD;
           the glucuronidation of ethinylestradiol. Mol Pharmacol 1993; 43(4):649-654.&#xD;
&#xD;
        9. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions&#xD;
           between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2(8):473-481.&#xD;
&#xD;
       10. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS&#xD;
           Drugs 2002 ;16 (4 ):263 -72 2002; 16(4):263-272.&#xD;
&#xD;
       11. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or&#xD;
           carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone&#xD;
           and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 2003 Apr&#xD;
           ;44 (4 ):540 -9 44(4):540-549.&#xD;
&#xD;
       12. Holdish T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on the pharmacology&#xD;
           of the combined oral contraceptive pill. Epilepsia 32[suppl. 1], s96. 1991.&#xD;
&#xD;
       13. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients&#xD;
           with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol&#xD;
           1997; 43(5):457-465.&#xD;
&#xD;
       14. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine&#xD;
           plasma levels. Neurology 2003 Aug 26 ;61 (4 ):570 -1 2003; 61(4):570-571.&#xD;
&#xD;
       15. Sabers A, Buchholt JM, ULDALL P, Hansen EL. Lamotrigine plasma levels reduced by oral&#xD;
           contraceptives. Epilepsy Res 2001 Nov ;47 (1 -2 ):151 -4 47(1-2):151-154.&#xD;
&#xD;
       16. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces&#xD;
           lamotrigine serum concentrations. Epilepsia 2005; 46(9):1414-1417.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2003</start_date>
  <completion_date>May 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The dose corrected trough concentration of lamotrigine following 21 days of placebo treatment compared to the dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints; the trough concentration of lamotrigine following 7 days of pause with the oral contraceptive pill, and the proportion of lamotrigine to lamotrigine metabolites found in urine samples following treatment with placebo and the o</measure>
  </secondary_outcome>
  <enrollment>10</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral contraception</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women with epilepsy, treated with lamotrigine in monotherapy and taking combination type&#xD;
        oral contraceptives, and who were between 18 and 40 years of age, were candidates for&#xD;
        inclusion in the study. Patients should agree to use contraception of barrier type&#xD;
        throughout the study (see study design).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients were not admitted to the study if any of the following criteria were present: (1)&#xD;
        pregnancy, (2) breastfeeding, (3) affected liver function, (4) affected kidney function,&#xD;
        (5) daily intake of drugs with known or suspected influence on the metabolism of&#xD;
        lamotrigine (acetaminophen and sertralin).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Christensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Aarhus University Hospital, 8000 Aarhus C</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.dkma.dk</url>
    <description>Danish Medicines Agency</description>
  </link>
  <reference>
    <citation>French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee. Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004 May;45(5):410-23. Review. Erratum in: Epilepsia. 2004 Nov;45(11):1299.</citation>
    <PMID>15101822</PMID>
  </reference>
  <reference>
    <citation>French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004 May;45(5):401-9. Review.</citation>
    <PMID>15101821</PMID>
  </reference>
  <reference>
    <citation>Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003 Jun;2(6):347-56. Review.</citation>
    <PMID>12849151</PMID>
  </reference>
  <reference>
    <citation>Depot M, Powell JR, Messenheimer JA Jr, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther. 1990 Oct;48(4):346-55.</citation>
    <PMID>2225696</PMID>
  </reference>
  <reference>
    <citation>Shipkova M, Wieland E. Glucuronidation in therapeutic drug monitoring. Clin Chim Acta. 2005 Aug;358(1-2):2-23. Review.</citation>
    <PMID>15893300</PMID>
  </reference>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>December 14, 2005</study_first_submitted>
  <study_first_submitted_qc>December 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Lamotrigine</keyword>
  <keyword>Oral Contraceptives</keyword>
  <keyword>UGT</keyword>
  <keyword>Glucuronidation.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

